Effect of a novel artificial intelligence–based cecum recognition system on adenoma detection metrics in a screening colonoscopy setting

IF 6.7 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Gastrointestinal endoscopy Pub Date : 2025-02-01 DOI:10.1016/j.gie.2024.09.019
Wen-Feng Hsu MD, PhD , Wei-Yuan Chang MD, MS , Chen-Ya Kuo MD , Li-Chun Chang MD, PhD , Hsuan-Ho Lin MD, MS , Ming-Shiang Wu MD, PhD , Han-Mo Chiu MD, PhD
{"title":"Effect of a novel artificial intelligence–based cecum recognition system on adenoma detection metrics in a screening colonoscopy setting","authors":"Wen-Feng Hsu MD, PhD ,&nbsp;Wei-Yuan Chang MD, MS ,&nbsp;Chen-Ya Kuo MD ,&nbsp;Li-Chun Chang MD, PhD ,&nbsp;Hsuan-Ho Lin MD, MS ,&nbsp;Ming-Shiang Wu MD, PhD ,&nbsp;Han-Mo Chiu MD, PhD","doi":"10.1016/j.gie.2024.09.019","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and Aims</h3><div>Cecal intubation in colonoscopy relies on self-reporting. We developed an artificial intelligence–based cecum recognition system (AI-CRS) for post-hoc verification of cecal intubation and explored its impact on adenoma metrics.</div></div><div><h3>Methods</h3><div>Quality metrics, including cecal intubation rate (CIR), adenoma detection rate (ADR), and other ADR-related metrics, were compared both before (2015-2018) and after (2019-2022) the implementation of the AI-CRS.</div></div><div><h3>Results</h3><div>Although the CIR did not change significantly after the implementation of the AI-CRS, the ADR and advanced ADR significantly increased. Although the ADR significantly increased in all segments, the most significant increase in advanced ADR was observed in the proximal colon. Implementation of the AI-CRS was associated with a higher likelihood of detecting adenoma (adjusted odds ratio, 1.35; 95% confidence interval, 1.26-1.45) and advanced adenoma (adjusted odds ratio, 1.23; 95% confidence interval, 1.07-1.41), respectively.</div></div><div><h3>Conclusions</h3><div>Implementation of a post-hoc verification of cecal intubation using an AI-CRS significantly improved various adenoma metrics in screening colonoscopy.</div></div>","PeriodicalId":12542,"journal":{"name":"Gastrointestinal endoscopy","volume":"101 2","pages":"Pages 452-455"},"PeriodicalIF":6.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastrointestinal endoscopy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0016510724035016","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and Aims

Cecal intubation in colonoscopy relies on self-reporting. We developed an artificial intelligence–based cecum recognition system (AI-CRS) for post-hoc verification of cecal intubation and explored its impact on adenoma metrics.

Methods

Quality metrics, including cecal intubation rate (CIR), adenoma detection rate (ADR), and other ADR-related metrics, were compared both before (2015-2018) and after (2019-2022) the implementation of the AI-CRS.

Results

Although the CIR did not change significantly after the implementation of the AI-CRS, the ADR and advanced ADR significantly increased. Although the ADR significantly increased in all segments, the most significant increase in advanced ADR was observed in the proximal colon. Implementation of the AI-CRS was associated with a higher likelihood of detecting adenoma (adjusted odds ratio, 1.35; 95% confidence interval, 1.26-1.45) and advanced adenoma (adjusted odds ratio, 1.23; 95% confidence interval, 1.07-1.41), respectively.

Conclusions

Implementation of a post-hoc verification of cecal intubation using an AI-CRS significantly improved various adenoma metrics in screening colonoscopy.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于人工智能的新型盲囊识别系统对结肠镜筛查中腺瘤检测指标的影响
背景和目的:结肠镜检查的盲肠插管依赖于自我报告。我们开发了一种基于人工智能的盲肠识别系统(AI-CRS),用于盲肠插管的事后验证,并探讨了其对腺瘤指标的影响:比较了 AI-CRS 实施前(2015-2018 年)和实施后(2019-2022 年)的质量指标,包括盲肠插管率(CIR)、腺瘤检出率(ADR)和其他 ADR 相关指标:虽然 CIR 在实施 AI-CRS 后没有明显变化,但 ADR 和 AADR 显著增加。虽然 ADR 在所有区段都有明显增加,但在近端结肠观察到的 AADR 增加最为明显。AI-CRS的实施分别与发现腺瘤(aOR=1.35,95%CI=1.26-1.45)和晚期腺瘤(aOR=1.23,95%CI=1.07-1.41)的可能性增加有关:使用 AI-CRS 对盲肠插管进行事后验证可显著改善筛查结肠镜检查中的各种腺瘤指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Gastrointestinal endoscopy
Gastrointestinal endoscopy 医学-胃肠肝病学
CiteScore
10.30
自引率
7.80%
发文量
1441
审稿时长
38 days
期刊介绍: Gastrointestinal Endoscopy is a journal publishing original, peer-reviewed articles on endoscopic procedures for studying, diagnosing, and treating digestive diseases. It covers outcomes research, prospective studies, and controlled trials of new endoscopic instruments and treatment methods. The online features include full-text articles, video and audio clips, and MEDLINE links. The journal serves as an international forum for the latest developments in the specialty, offering challenging reports from authorities worldwide. It also publishes abstracts of significant articles from other clinical publications, accompanied by expert commentaries.
期刊最新文献
Erratum Contents Prospective randomized controlled trial of water exchange plus cap versus water exchange colonoscopy in unsedated veterans Boosting efficiency in the endoscopy suite: integrating team workflows improves productivity and minimizes cost Glucagon-like peptide-1 receptor agonists and capsule endoscopy in patients with diabetes: a matched cohort study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1